Clinical Scorecard: New Marker for Aggressive Prostate Cancer

At a Glance

Key Highlights

• FOXA1 shows high sensitivity for prostate adenocarcinoma.
• Detectable in many cases of small cell carcinoma of the prostate.
• Conventional markers often lost in aggressive prostate cancer cases.
• Positive FOXA1 staining supports prostatic origin in ambiguous cases.
• FOXA1 may aid in evaluating metastatic neuroendocrine tumors.

Guideline-Based Recommendations

Diagnosis

• Utilize FOXA1 as an adjunct immunohistochemical marker.

Management

• Consider FOXA1 in the context of treatment-resistant prostate cancers.

Monitoring & Follow-up

• Further validation studies needed to confirm clinical utility.

Risks

• Potential misdiagnosis due to loss of conventional markers.

Patient & Prescribing Data

Patients with prostate cancer, especially those with small cell carcinoma.

FOXA1 may assist in identifying the tissue of origin in metastatic cases.

Clinical Best Practices

• Incorporate FOXA1 staining in diagnostic evaluations of prostate cancer.
• Use FOXA1 to differentiate between prostate and other neuroendocrine tumors.

Related Resources & Content

• Histopathology Study